Skip to main content
IMUGENE LIMITED logo

IMUGENE LIMITED — Investor Relations & Filings

Ticker · IMU ISIN · AU000000IMU9 LEI · 984500A5C9KF08EAF248 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,444 across all filing types
Latest filing 2004-09-30 Investor Presentation
Country AU Australia
Listing ASX IMU

About IMUGENE LIMITED

https://imugene.com

Imugene Limited is a clinical-stage immuno-oncology company focused on developing immunotherapies to activate the immune system against various cancers. The company’s pipeline features multiple platform technologies, including B-cell activating immunotherapies, oncolytic viruses, and CAR-T cell enhancement therapies. Key clinical candidates include HER-Vaxx, targeting HER2-positive gastric cancer, and PD1-Vaxx, a checkpoint inhibitor immunotherapy. Imugene is also advancing the CF33 oncolytic virus platform, which includes VAXINIA and CHECKvacc, alongside the onCARlytics program. The onCARlytics platform is designed to enable CAR-T cells to target solid tumors by inducing the expression of CD19 on cancer cell surfaces. These programs aim to address unmet needs in oncology by providing targeted, potent, and potentially less toxic alternatives to conventional treatments.

Recent filings

Filing Released Lang Actions
Presentation to the Australian Biotech Expo 22 pages ?Kb
Investor Presentation Classification · 95% confidence The document is a conference presentation from October 2004 by Dr. Warwick Lamb, Managing Director of IVUGENI Animal Health Biological Products. It contains slides with product descriptions, technology explanations, market potential, management team, capital structure, and shareholder value focus. There are no financial statements, regulatory filings, or formal report structures. The content is clearly a detailed presentation aimed at investors or stakeholders about the company's technology, products, and business strategy. Therefore, it fits the category of an Investor Presentation (IP). The document length (6833 characters) and the presence of multiple slides with graphics and bullet points support this classification.
2004-09-30 English
Receptor Mimic Technology to be Commercialised for Humans 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 September 2004 from Imugene Limited regarding securing license options for Receptor Mimic Technology for all animal species. It discusses the company's business development and licensing agreements but does not contain financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about a licensing agreement and business update rather than a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. It is not a management change, voting result, or legal proceeding. The content fits best as a general regulatory announcement about business development and licensing. Therefore, the most appropriate classification is Regulatory Filings (RNS). The confidence in this classification is high given the nature and content of the document.
2004-09-15 English
Receptor Mimic Technology to be Commercialised for Humans 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 September 2004 describing a new company formation and commercialisation plans for a technology called Receptor Mimic Technology (RMT). It discusses licensing agreements, ownership percentages, board involvement, and funding requirements. There are no financial statements, quarterly or annual results, nor any regulatory certifications or voting results. The content focuses on a corporate development and strategic partnership rather than financial performance or governance changes. It is not a report but an announcement of a corporate transaction and strategic update. Therefore, the most appropriate classification is a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2004-09-15 English
Secures Receptor Mimic Technology for all Animal Species 3 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 16 September 2004 from Imugene Limited. It discusses the company securing license options for its Receptor Mimic Technology for animal species. The content is a corporate announcement about a licensing agreement and business development, not a financial report or regulatory filing. It does not contain financial statements, audit information, management changes, or voting results. It is a typical capital/financing update or business development announcement related to licensing and technology rights. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is about 4954 characters, which is consistent with an announcement rather than a full report.
2004-09-15 English
Appendix 3B - Conversion of Unlisted Options/S 708A Notice 9 pages ?Kb
Capital/Financing Update Classification · 95% confidence The document is titled 'Appendix 3B' and is a new issue announcement related to securities issued by Imugene Limited. It includes details about the class of securities, number issued, issue price, purpose of the issue, and other related information. The document references ASX rules and is a formal announcement of a capital raising event or securities issuance. It does not contain financial statements, management discussion, or audit information. It is not a full report but an announcement of a capital/financing update. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed issuance information, supporting a high confidence in classification.
2004-09-01 English
Preliminary Final Report & Full Year Accounts 54 pages ?Kb
Annual Report Classification · 95% confidence The document is titled 'PRELIMINARY FINAL REPORT FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2004' and includes detailed financial data for the full fiscal year ending June 30, 2004. It references an Appendix 4E, which is a regulatory form used in Australia for preliminary final reports, and contains comprehensive financial statements such as Statement of Financial Performance, Position, Cash Flows, Directors' Report, Corporate Governance Statement, and an Independent Audit Report. The document is lengthy (15,000 characters) and contains substantive financial data and management commentary. This matches the characteristics of an Annual Report (10-K equivalent) rather than a brief announcement or a regulatory filing. Therefore, the document should be classified as an Annual Report (10-K).
2004-08-30 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.